Annals of Emergency Medicine
Volume 52, Issue 1 , Pages 48-58.e2 , July 2008

Risk Prediction With Procalcitonin and Clinical Rules in Community-Acquired Pneumonia

Presented at the American College of Emergency Physicians Research Forum, October 2006, New Orleans, LA.

  • David T. Huang, MD, MPH

      Affiliations

    • Clinical Research, Investigation, and Systems Modeling of Acute Illness Laboratory, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
    • Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, PA
    • Corresponding Author InformationAddress for correspondence: David T. Huang, MD, MPH, Room 646B Scaife Hall, The CRISMA Laboratory, Department of Critical Care Medicine, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261; 412-647-6818, fax 412-647-3791
    • ,
  • Lisa A. Weissfeld, PhD

      Affiliations

    • Clinical Research, Investigation, and Systems Modeling of Acute Illness Laboratory, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
    • Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA
    • ,
  • John A. Kellum, MD

      Affiliations

    • Clinical Research, Investigation, and Systems Modeling of Acute Illness Laboratory, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
    • ,
  • Donald M. Yealy, MD

      Affiliations

    • Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, PA
    • ,
  • Lan Kong, PhD

      Affiliations

    • Clinical Research, Investigation, and Systems Modeling of Acute Illness Laboratory, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
    • Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA
    • ,
  • Michael Martino, MD

      Affiliations

    • Department of Emergency Medicine, Jefferson Regional Medical Center, Pittsburgh, PA.
    • ,
  • Derek C. Angus, MD, MPH

      Affiliations

    • Clinical Research, Investigation, and Systems Modeling of Acute Illness Laboratory, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
    • ,
  • GenIMS Investigators

Received 23 October 2007 ,Revised 21 December 2007 ,Accepted 8 January 2008.

References 

  1. DeFrances CJ, Podgornik MN. 2004 National Hospital Discharge Survey. Adv Data. 2006;371:1–19
  2. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20:820–837
  3. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–1310
  4. Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med. 2002;165:766–772
  5. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250
  6. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382
  7. American College of Emergency Physicians. Clinical policy for the management and risk stratification of community-acquired pneumonia in adults in the emergency department. Ann Emerg Med. 2001;38:107–113
  8. Yealy DM, Auble TE, Stone RA, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med. 2005;143:881–894
  9. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care and evaluation of the American Thoracic Society and British Thoracic Society criteria. Am J Respir Crit Care Med. 2002;166:717–723
  10. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24:971–983
  11. Christ-Crain M, Muller B. Procalcitonin in bacterial infections—hype, hope, more or less?. Swiss Med Wkly. 2005;135:451–460
  12. Luzzani A, Polati E, Dorizzi R, et al. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003;31:1737–1741
  13. Casado-Flores J, Blanco-Quiros A, Asensio J, et al. Serum procalcitonin in children with suspected sepsis: a comparison with C-reactive protein and neutrophil count. Pediatr Crit Care Med. 2003;4:190–195
  14. Caterino JM, Scheatzle MD, Forbes ML, et al. Bacteremic elder emergency department patients: procalcitonin and white count. Acad Emerg Med. 2004;11:393–396
  15. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34:1996–2003
  16. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin-guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174:84–93
  17. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131:9–19
  18. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–607
  19. Tang BM, Eslick GD, Craig JC, et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis. 2007;7:210–217
  20. Jones AE, Fiechtl JF, Brown MD, et al. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med. 2007;50:34–41
  21. Masia M, Gutierrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the Patients Outcome Research Team Pneumonia Severity Index. Chest. 2005;128:2223–2229
  22. Beovic B, Kreft S, Osredkar J, et al. Serum procalcitonin levels in patients with mild community-acquired pneumonia. Clin Microbiol Infect. 2005;11:1050–1051
  23. Nylen E, Muller B, Becker KL, et al. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis. 2003;36:823–824
  24. Steinbach G, Rau B, Debard AL, et al. Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor System. Clin Chem Lab Med. 2004;42:440–449
  25. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med. 2005;118:384–392
  26. Richter SS, Beekmann SE, Croco JL, et al. Minimizing the workup of blood culture contaminants: implementation and evaluation of a laboratory-based algorithm. J Clin Microbiol. 2002;40:2437–2444
  27. Weinstein MP. Blood culture contamination: persisting problems and partial progress. J Clin Microbiol. 2003;41:2275–2278
  28. Metersky ML, Ma A, Bratzler DW, et al. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med. 2004;169:342–347
  29. Graham JC, Galloway A. ACP Best Practice No 167: the laboratory diagnosis of urinary tract infection. J Clin Pathol. 2001;54:911–919
  30. In:  Mayhall C,  Horan TC,  Gaynes R editor. Hospital Epidemiology and Infection Control. Philadelphia, PA: Lippincott Williams & Wilkins; 2004;p. 1659–1702
  31. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults (Infectious Diseases Society of America). Clin Infect Dis. 2000;31:347–382
  32. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia (Diagnosis, assessment of severity, antimicrobial therapy, and prevention). Am J Respir Crit Care Med. 2001;163:1730–1754
  33. Granato PA. Pathogenic and indigenous microorganisms of humans. In:  Murray PR editors. Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology Press; 2003;p. 44–54
  34. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions conference. Intensive Care Med. 2003;29:530–538
  35. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34:344–353
  36. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ. 2004;329:168–169
  37. Yealy DM, Auble TE, Stone RA, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med. 2005;143:881–894
  38. Wenzel RP, Fowler AA. Acute bronchitis. N Engl J Med. 2006;355:2125–2130
  39. Reiling J. JAMA 100 years ago: the laboratory in diagnosis. JAMA. 2007;297:538
  40. Marrie TJ, Lau CY, Wheeler SL, et al. CAPITAL Study Investigators A controlled trial of a critical pathway for the treatment of community acquired pneumonia (Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin). JAMA. 2000;283:749–755
  41. Macfarlane JT, Boldy D. 2004 Update of BTS pneumonia guidelines: what's new?. Thorax. 2004;59:364–366
  42. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27–S72
  43. Marrie TJ, Huang JQ. Admission is not always necessary for patients with community-acquired pneumonia in risk classes IV and V diagnosed in the emergency room. Can Respir J. 2007;14:212–216
  44. Schelbert E. Prognostic value of B-type natriuretic peptide in unstable coronary artery disease. JAMA. 2006;295:1895–1896

 Supervising editors: Gregory J. Moran, MD; Judd E. Hollander, MD

 Dr. Moran and Dr. Hollander were the supervising editors on this article. Dr. Yealy did not participate in the editorial review or decision to publish this article.

 Author contributions: DTH, LAW, JAK, DMY, and DCA conceived and designed the study, analyzed and interpreted the data, and provided important critical revisions of the article. DTH, DMY and DCA drafted the article. DTH, JAK, DMY, and DCA provided final approval. LAW and LK provided statistical expertise. LAW also contributed to drafting of the article, and LK contributed to analysis and interpretation of the data. JAK and DCA obtained funding for the study. JAK, MM, and DCA provided administrative, technical, and logistic support. MM also contributed to analysis and interpretation of the data and article revision. DTH takes responsibility for the paper as a whole.

 Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article, that might create any potential conflict of interest. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. Funding received from: NIGMS R01 GM061992. DTH, LAW, LK, DCA have provided consulting work to BRAHMS Diagnostica, the manufacturer of the procalcitonin assay used in this study. DTH has received one speaking honorarium and travel expenses for presentation at a satellite symposium of the September 2006 European Respiratory Society meeting in Munich, Germany. BRAHMS Diagnostica covered sample shipping and procalcitonin assay costs; no direct monetary grant support was provided.

 Publication dates: Available online March 17, 2008.

 Reprints not available from the authors.

PII: S0196-0644(08)00030-9

doi: 10.1016/j.annemergmed.2008.01.003

Annals of Emergency Medicine
Volume 52, Issue 1 , Pages 48-58.e2 , July 2008

Article Tools

* Image Usage & Resolution